Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP (107-139) to ovariectomized mice

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1752-1760

  de Castro, Luis Fernández ^a   Lozano, Daniel ^a   Portal Núñez, Sergio ^a   Maycas, Marta ^a   de la Fuente, Mónica ^b   Caeiro, José R ^c   Esbrit, Pedro ^a  

^a UAM)   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Empresa de Base Tecnológica S L   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CATALASE; CATHEPSIN K; CYCLIN D1; DICKKOPF 1 PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN [1-36]; PARATHYROID HORMONE RELATED PROTEIN [107-139]; SCLEROSTIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HISTOLOGY; METAPHYSIS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OVARIECTOMY; OXIDATIVE STRESS; PRIORITY JOURNAL; TIBIA; UPREGULATION;

ANIMALS; BONE REMODELING; BONE RESORPTION; FEMALE; GLYCOPROTEINS; INJECTIONS, SUBCUTANEOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; OSTEOGENESIS; OXIDATIVE STRESS; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; RNA, MESSENGER;

MUS;

EID: 84855723440     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22902     Document Type: Article

References (53)

1. Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M. 2001. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16:1665-1673.
2. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. 2007. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285-27297.
3. Alonso V, de Gortázar AR, Ardura JA, Andrade-Zapata I, Alvarez-Arroyo MV, Esbrit P. 2008. Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 217:717-727.
4. Arranz L, Caamaño JH, Lord JM, De la Fuente M. 2010. Preserved immune functions and controlled leukocyte oxidative stress in naturally long-lived mice: Possible role of nuclear factor kappa B. J Gerontol A Biol Sci Med Sci 65:941-950.
5. Bisello A, Horwitz MJ, Stewart AF. 2004. Parathyroid hormone-related protein: An essential physiological regulator of adult bone mass. Endocrinology 145:3551-3553.
6. Boileau G, Tenenhouse HS, Desgroseillers L, Crine P. 2001. Characterization of PHEX endopeptidase catalytic activity: Identification of parathyroid-hormone-related peptide 107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 355:707-713.
7. Cano A, Dapía S, Noguera I, Pineda B, Hermenegildo C, del Val R, Caeiro JR, García-Pérez MA. 2008. Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice. Osteoporos Int 19:793-800.
8. Compston JE. 2007. Skeletal actions of intermittent parathyroid hormone: Effects on bone remodeling and structure. Bone 40:1447-1452.
9. Cornish J, Callon KE, Nicholson GC, Reid IR. 1997. Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. Endocrinology 138:1299-1304.
10. Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. 1999. Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 14:915-922.
11. 107] (107-139). Biochim Biophys Acta 1432:64-72.
12. de Castro LF, Lozano D, Dapía S, Portal-Núñez S, Caeiro JR, Gómez-Barrena E, Esbrit P. 2010. Role of the N- and C-terminal fragments of parathyroid hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 16:1157-1168.
13. de Gortázar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P. 2006. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 79:360-369.
14. Dean T, Vilardaga JP, Potts JT, Jr., Gardella TJ. 2008. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 22:156-166.
15. Fenton AJ, Kemp BE, Kent GN, Moseley JM, Zheng MH, Rowe DJ, Britto JM, Martin TJ, Nicholson GC. 1991a. A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts. Endocrinology 129:1762-1768.
16. Fenton AJ, Kemp BE, Hammonds RG, Jr., Mitchelhill K, Moseley JM, Martin TJ, Nicholson GC. 1991b. A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormne-related protein; PTHrP (107-111). Endocrinology 129:3424-3426.
17. Fenton AJ, Martin TJ, Nicholson GC. 1993. Long-term culture of disaggregated rat osteoclasts: Inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP [107-139]. J Cell Physiol 155:1-7.
18. Fritton JC, Emerton KB, Sun H, Kawashima Y, Mejia W, Wu Y, Rosen CJ, Panus D, Bouxsein M, Majeska RJ, Schaffler MB, Yakar S. 2010. Growth hormone protects against ovariectomy-induced bone loss in states of low circulating insulin-like growth factor (IGF-1). J Bone Miner Res 25:235-246.
19. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132-33140.
20. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
21. Glatt V, Canalis E, Stadmeyer L, Bouxsein ML. 2007. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 22:1197-1207.
22. Hildreth BE, Hildreth BE III, Werbeck JL, Thudi NK, Deng X, Rosol TJ, Toribio RE. 2010. PTHrP 1-141 and 1-86 in crease in vitro bone formation. J Surg Res 16:e9-e17.
23. Horwitz MJ, Tedesco MB, Gundberg C, García-Ocaña A, Stewart AF. 2003. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569-575.
24. Horwitz MJ, Tedesco MB, García-Ocaña A, Sereika SM, Prebehala L, Bisello A, Hollis BW, Gundberg CM, Stewart AF. 2010. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: Defining the maximal tolerable dose. J Clin Endocrinol Metab 95:1279-1287.
25. Keller H, Kneissel M. 2005. SOST is a target gene for PTH in bone. Bone 37:148-158.
26. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE. 2005. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95:1178-1190.
27. Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ. 2003. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112:915-923.
28. Li CY, Schaffler MB, Wolde-Semait HT, Hernández CJ, Jepsen KJ. 2005. Genetic background influences cortical bone response to ovariectomy. J Bone Miner Res 20:2150-2158.
29. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588.
30. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L. 2009. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24:1651-1661.
31. López-Herradón A, Lozano D, Portal-Núñez S, Fernández de Castro L, Esbrit P. 2010. Both N- and C-terminal fragments of parathyroid hormone-related protein counteracts the inhibition of the Wnt/β-catenin pathway in mice with diabetes-related osteopenia. Bone 47:S46 (abstract).
32. Lozano D, de Castro LF, Dapía S, Andrade-Zapata I, Manzarbeitia F, Alvarez-Arroyo MV, Gómez-Barrena E, Esbrit P. 2009. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 150:2027-2035.
33. Lozano D, Fernández-de-Castro L, Portal-Núñez S, López-Herradón A, Dapía S, Gómez-Barrena E, Esbrit P. 2011. The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low turnover osteopenia. Br j Pharmacol 162:1424-1438.
34. Martínez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martínez ME. 2002. Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells. Osteoporosis Int 13:874-881.
35. Miao D, He B, Jiang Y, Kobayashi T, Sorocéanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC. 2005. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115:2402-2411.
36. Miao D, Su H, He B, Gao J, Xia Q, Zhu M, Gu Z, Goltzman D, Karaplis AC. 2008. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci USA 105:20309-20311.
37. Mody N, Parhami F, Sarafian TA, Demer LL. 2001. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 31:509-519.
38. Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL. 2010. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 87:99-107.
39. Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Isaacs RJ, Mendoza E, Barbier J-R. 1999. Prolonged low-dose infusion of human parathyroid hormone does not increase femoral cancellous bone volume in ovariectomized rats. Eur J Endocrinol 141:70-74.
40. Nemoto S, Finkel T. 2002. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295:2450-2452.
41. Padhi D, Jang G, Stouch B, Fang L, Posvar E. 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26.
42. Portal-Núñez S, Lozano D, Fernández de Castro L, de Gortázar AR, Nogués X, Esbrit P. 2010. Alterations of the Wnt/β-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett 584:3095-30100.
43. Rihani-Basharat S, Lewinson D. 1997. PTHrP (107-111) inhibits in vivo resorption that was stimulated by PTHrP (1-34) when applied intermittently to neonatal mice. Calcif Tissue Int 61:426-428.
44. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
45. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM. 2000. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517-1525.
46. Toribio RE, Brown HA, Novince CM, Marlow B, Hernon K, Lanigan LG, Hildreth BE III, Werbeck JL, Shu ST, Lorch G, Carlton M, Foley J, Boyaka P, McCauley LK, Rosol TJ. 2010. The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J 24:1947-1957.
47. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ, Jr., DiStefano PS, Chiang LW, Greenberg ME. 2002. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296:530-534.
48. Turgeman G, Zilberman Y, Zhou S, Kelly P, Moutsatsos IK, Kharode YP, Borella LE, Bex FJ, Komm BS, Bodine PV, Gazit D. 2002. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem 86:461-474.
49. Turner RT. Mice, estrogen, and postmenopausal osteoporosis. J Bone Miner Res 1999. 14:187-191.
50. Valín A, Guillén C, Esbrit P. 2001. C-terminal parathyroid hormone-related protein (PTHrP) (107-139) stimulates intracellular Ca(2+) through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells. Endocrinology 142:2752-2759.
51. Zhang Y, Dong X-L, Leung P-C, Wong M-S. 2009. Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet. Bone 44:46-52.
52. Zheng MH, McCaughan HB, Papadimitriou JM, Nicholson GC, Wood DJ. 1994. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein. J Cell Biochem 54:145-153.
53. Zhou H, Iida-Klein A, Lu SS, Ducayen-Knowles M, Levine LR, Dempster DW, Lindsay R. 2003. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513-520.